Immuneering Corporation IMRX
Updated: 10 Aug 2026
No signal published yet
We already track Immuneering and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Immuneering Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immuneering free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, Immuneering reported its second-quarter 2026 financial results, ending the period with $182.7 million in cash, cash equivalents, and marketable securities. The company expects this liquidity to fund operations into 2029 as it advances its pivotal Phase 3 MAPKeeper 301 trial of atebimetinib in first-line pancreatic cancer.
What Firelda Watch includes for Immuneering Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Immuneering Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immuneering free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more